GHENT, Belgium, 16 February 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its full year results for 2016 on Thursday 23 February 2017 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2016 will be presented, followed by a Q&A session. This event will be held on Thursday 23 February 2017 at 4.00 pm CET/10.00 am EST.
The conference call will be webcast live and may be accessed by clicking here. If you would like to participate in the Q&A session, please dial +32(0)2 402 3092, confirmation code 8519613. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under the http://www.ablynx.com/news/events-presentations/.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Director IR & Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire